Ionis Pharmaceuticals Inc revenue
Ionis Pharmaceuticals Inc's revenue was $944m in fiscal 2025, up 33.8% on the year before. Since fiscal 2009 ($122m) it has grown at a compound 13.7% a year. Over the last twelve months it was $874m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 122 | 108 | 99 | 102 | 147 | 214 | 284 | 347 | 508 | 600 | 1,123 | 729 | 810 | 587 | 788 | 705 | 944 | 874 |
| Growth on the year before | — | −10.8% | −8.7% | +3.0% | +44.3% | +45.4% | +32.5% | +22.2% | +46.5% | +18.1% | +87.2% | −35.0% | +11.1% | −27.5% | +34.1% | −10.5% | +33.8% | — |
| Gross profit | — | — | — | — | — | — | — | 347 | 508 | 598 | 1,118 | 717 | 800 | 573 | 779 | 694 | 928 | 858 |
| Gross margin | — | — | — | — | — | — | — | 100.0% | 100.0% | 99.7% | 99.6% | 98.4% | 98.7% | 97.6% | 98.8% | 98.4% | 98.3% | 98.2% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Research and Development Revenue | $508M | ▲ 23.2% |
| Collaborative Agreement Revenue | $466M | ▲ 40.0% |
| Commercial | $436M | ▲ 48.7% |
| Royalty | $286M | ▲ 11.0% |
| Spinraza Royalties | $212M | ▼ 1.8% |
| Products | $115M | — |
| Tryngolza Sales | $108M | — |
| Wainus Royalties | $49.1M | ▲ 142.9% |
| Wainua Joint Development Revenue | $42.1M | ▼ 47.0% |
| Other Commercial | $35M | ▼ 2.1% |
| Other Royalties | $24.2M | ▲ 15.0% |
| Dawnzera Sales | $7.8M | — |
These categories overlap or exclude eliminations, so shares aren't shown.
From Ionis Pharmaceuticals Inc's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Ionis Pharmaceuticals Inc | $874m | -7.4% | 11.5% |
| Ascendis Pharma A/s | $814m | 106.9% | — |
| Biocryst Pharmaceuticals Inc | $941m | 68.7% | 45.3% |
| Bridgebio Pharma, Inc. | $946m | 167.3% | 364.6% |
| Kiniksa Pharmaceuticals International, plc | $946m | 58.2% | 56.1% |
| Telix Pharmaceuticals Ltd | $804m | 55.6% | — |
Compare with peers
- Ascendis Pharma A/s revenue
- Biocryst Pharmaceuticals Inc revenue
- Bridgebio Pharma, Inc. revenue
- Kiniksa Pharmaceuticals International, plc revenue
- Telix Pharmaceuticals Ltd revenue
Head to head: ASND vs IONSBCRX vs IONSBBIO vs IONSIONS vs KNSA
More: Biotechnology stocks compared, Health Care sector, rankings of US companies